EMOTION: MBK-01 in NASH

Phase 2, randomised, double-blind trial of MBK-01 in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by IDIVAL. Primary endpoints: Proportion of patients with improvement of fat fraction by proton density by MRI and no worsening of activity or fibrosis at 72 weeks and Number of adverse events (AEs), serious AEs, AEs resulting in discontinuation, AEs of special interest, and changes in vital signs and laboratory values at 72 weeks. Planned start Jan 2024; status: not yet recruiting.